Treating diabetic nephropathy--are there only economic issues?
Mitch
William E
WE
Renal Division, University of Texas Medical Branch, Galveston, USA
D000419:Albuminuria / Q000517:prevention & control; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000191:economics / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D014481:United States
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers